Key facts
- This page summarizes Christopher D. Galloway's Form 4 filing for Diffusion Pharmaceuticals Inc. (CRVO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 31 Jan 2022, 05:06.
Christopher D. Galloway - 27 Jan 2022 Form 4 Insider Report for Diffusion Pharmaceuticals Inc. (CRVO)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- CRVO
- Reported as of
- 27 Jan 2022
- Net transaction value
- $0
- Reporting owner signature
- /s/ William R. Elder, attorney-in-fact for the Reporting Person
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Christopher D. Galloway filed Form 4 for Diffusion Pharmaceuticals Inc. (CRVO) on 31 Jan 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DFFN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +305,743
- Change %
- Price
- $0.000000
- Shares after
- 305,743
- Date
- 27 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 305,743
- Exercise price
- $0.2400
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing January 31, 2022.